Background An unmet need exists for focal segmental glomerulosclerosis (FSGS) treatment.
In an 8-week, phase 2 trial, sparsentan, a dual endothelin–angiotensin receptor antagonist …

Background Sparsentan, a novel, non-immunosuppressive, single-molecule, dual
endothelin angiotensin receptor antagonist, significantly reduced proteinuria versus …

Abstract Sodium–glucose cotransporter 2 (SGLT2) inhibitors were initially developed for
their glucose-lowering effects and have shown a modest glycaemic benefit in people with …

Objective To determine whether adding obinutuzumab to standard‐of‐care lupus nephritis
(LN) therapy could improve the likelihood of long‐term preservation of kidney function and …

Nephropathy is one of the main features of Fabry disease (FD) that leads, in untreated
patients with classical mutations, to end-stage renal disease (ESRD) from the third to the fifth …

Background Sodium–glucose co-transporter-2 (SGLT2) inhibitors reduce progression of
chronic kidney disease and the risk of cardiovascular morbidity and mortality in a wide range …

Win statistics offer a new approach to the analysis of outcomes in clinical trials, allowing the
combination of time-to-event and longitudinal measurements and taking into account the …

Rationale & Objective The standard of care (SoC) group of randomized controlled trials
(RCTs) is a useful setting to explore the secular trends in kidney disease progression …

ABSTRACT Background Serum creatinine (SCr), mainly determined by the Jaffe or an
enzymatic method, is the central marker to assess kidney function. Deviations between …

Background: Intensive blood pressure (BP) lowering in SPRINT produced acute decreases
in kidney function and higher risk for acute kidney injury. We evaluated the effect of intensive …